Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.88 is 664% above its 5-year average of -0.16, near the high end of its 5-year range (-130.62–2.46).
As of the fiscal period ended Tuesday, June 30, 2026. 103.41% above its 12-month average of -25.94.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.88.
DEBT TO EQUITY RATIO
0.88
DEBT TO EQUITY RATIO AVG TTM
-25.94
DEBT TO EQUITY RATIO AVG 3Y
-0.31
DEBT TO EQUITY RATIO AVG 5Y
-0.16
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+103.41%
CURRENT VS 3Y AVG
+389.18%
CURRENT VS 5Y AVG
+663.54%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 516 covered companies
CURRENT VS SECTOR MEDIAN
+554.35%
vs the sector median at left
HCW Biologics Inc.
Market Cap
$566655.00
Debt to Equity Ratio
0.88
TTM Avg
-25.94
3Y Avg
-0.31
5Y Avg
-0.16
Market Cap
$667296.00
Debt to Equity Ratio
0.95
TTM Avg
1.02
3Y Avg
1.02
5Y Avg
4.80
Market Cap
$848259.00
Debt to Equity Ratio
0.01
TTM Avg
0.03
3Y Avg
0.06
5Y Avg
0.04
Market Cap
$874595.00
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$883067.00
Debt to Equity Ratio
0.00
TTM Avg
0.07
3Y Avg
0.05
5Y Avg
0.04
Market Cap
$893920.00
Debt to Equity Ratio
N/A
TTM Avg
0.01
3Y Avg
0.08
5Y Avg
0.06
Market Cap
$1.02M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$1.08M
Debt to Equity Ratio
0.14
TTM Avg
0.76
3Y Avg
0.50
5Y Avg
0.30
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HCW Biologics Inc. (HCWB) | $566655.00 | 0.88 | -25.94 | -0.31 | -0.16 |
| CDT Equity Inc. (CDT)vs › | $667296.00 | 0.95 | 1.02 | 1.02 | 4.80 |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $848259.00 | 0.01 | 0.03 | 0.06 | 0.04 |
| Bone Biologics Corporation (BBLG)vs › | $874595.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Decoy Therapeutics Inc. (DCOY)vs › | $883067.00 | 0.00 | 0.07 | 0.05 | 0.04 |
| GlucoTrack, Inc. (GCTK)vs › | $893920.00 | N/A | 0.01 | 0.08 | 0.06 |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | 0.00 | 0.00 | 0.00 | 0.00 |
| Akanda Corp. (AKAN)vs › | $61819.00 | N/A | 0.08 | 0.11 | 0.11 |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | 0.14 | 0.76 | 0.50 | 0.30 |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $31001.00 | 0.01 | 0.11 | 0.08 | 0.08 |
Debt/Equity
0.88
Current Ratio
0.06
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.88 |
| 2026-03-31 | 1.14 |
| 2025-12-31 | 2.46 |
| 2025-09-30 | -3.56 |
| 2025-06-30 | -130.62 |
| 2025-03-31 | -1.63 |
| 2024-12-31 | -2.02 |
| 2024-09-30 | -1.28 |
| 2024-06-30 | -1.59 |
| 2024-03-31 | 0.96 |
| 2023-12-31 | 0.47 |
| 2023-09-30 | 0.27 |
| 2023-06-30 | 0.23 |
| 2023-03-31 | 0.20 |
| 2022-12-31 | 0.17 |
| 2022-09-30 | 0.15 |
| 2022-06-30 | 0.01 |
| 2022-03-31 | 0.01 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.02 |
| 2020-12-31 | 0.04 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
